N-acetylcysteine as an anti-oxidant and anti-inflammatory drug and its some clinical applications

Central-European Journal of Immunology

Volumn 37, Issue 1, 2012, Pages 57-66

  Radomska Leśniewska, Dorota Magdalena ^a   Skopiński, Piotr ^a,b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Cancer; Contrast induced nephropathy; Endometriosis; Eye disorders; N acetylcysteine; Oxidative stress; Polycystic ovary syndrome; Pulmonary disease

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTHRACYCLINE; AZATHIOPRINE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BERBERINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CARNITINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CONTRAST MEDIUM; CORTICOSTEROID; CURCUMIN; DOXORUBICIN; ELLAGIC ACID; EPIGALLOCATECHIN GALLATE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; MELATONIN; PLACEBO; PREDNISONE; REACTIVE OXYGEN METABOLITE; RESVERATROL; RETINOL; SELENIUM DERIVATIVE; SODIUM SELENITE; THEOPHYLLINE; UBIDECARENONE; UNINDEXED DRUG; VASCULOTROPIN;

ACUTE KIDNEY FAILURE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADD ON THERAPY; ADENOMATOUS POLYP; ADJUVANT THERAPY; AIRWAY OBSTRUCTION; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CARDIOTOXICITY; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COLON CANCER; COLON POLYP; CONTRAST INDUCED NEPHROPATHY; CONTROLLED CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DNA DAMAGE; DOSE RESPONSE; DRUG INTOXICATION; DRUG MEGADOSE; DRY EYE; ENDOMETRIOSIS; EYE BURNING; FIBROSING ALVEOLITIS; GENOTOXICITY; GINSENG; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; IMMUNE DEFICIENCY; INFLUENZA; INSULIN SENSITIVITY; LOW DRUG DOSE; LYMPHOMA; MEIBOMIAN GLAND; MELANOMA; META ANALYSIS; NONHUMAN; OCULAR PRURITUS; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK FACTOR; SEBACEOUS GLAND DISEASE; SECOND CANCER; SJOEGREN SYNDROME; SUBRETINAL NEOVASCULARIZATION; SUPPLEMENTATION; TOXIC HEPATITIS; VITAMIN SUPPLEMENTATION;

EID: 84860307791     PISSN: 14263912     EISSN: 16444124     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Webb WR (1962): Clinical evaluation of a mucolytic agent, acetyl-cysteine. J Thorac Cardiovasc Surg 44: 330-343.
2. Ziment I (1986): Acetylcysteine: a drug with interesting past and fascinating future. Respiration 50: 26-30.
3. Sadowska AM, Verbraecken J, Darquennes K, De Backer WA (2006): Role of N-acetylcysteine in the management of COPD. Int J Chron Obstruct Pulmon Dis 1: 425-434.
4. Van Schooten FJ, Besaratinia A, De Flora S, et al. (2002): Effects of oral administration of N-acetyl-L-cysteine: a multi-biomarker study in smokers. Cancer Epidemiol Biomarkers Prev 11: 167-175. (Pubitemid 34202998)
5. Radomska-Leoeniewska DM, Skopińska-Rózewska E, Jankowska-Steifer E, et al. (2010): N-acetylcysteine inhibits IL-8 and MMP-9 release and ICAM-1 expression by bronchoalveolar cells from interstitial lung disease patients. Pharmacol Rep 62: 131-138.
6. Zafarullah M, Li WQ, Sylvester J, Ahmad M (2003): Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 60: 6-20. (Pubitemid 36223114)
7. Ścibiór-Bêtkowska D, Czeczot A (2009): Cancer cells and oxidative stress. Postêpy Hig Med Dosw 63: 58-72.
8. Lee YJ, Lee DM, Lee CH, et al. (2011): Suppression of human prostate cancer PC-3 cell growth by N-acetylcysteine involves over-expression of Cyr61. Toxicol In Vitro 25: 199-205.
9. Maher TM, Wells AU, Laurent GJ (2007): Idiopathic pulmonary fibrosis: multiple causes and multiple mechanism? Eur Respir J 30: 835-839. (Pubitemid 351194784)
10. Radomska-Leoeniewska DM, Sadowska AM, Van Overveld FJ, et al. (2006): Influence of N-acetylcysteine on ICAM-1 expression and IL-8 release from endothelial and epithelial cells. J Physiol Pharmacol 57: 325-334. (Pubitemid 44638216)
11. Ask K, Martin GE, Kolb M, Gauldie J (2006): Targeting genes for treatment in idiopathic pulmonary fibrosis: challenges and opportunities, promises and pitfalls. Proc Am Thorac Soc 3: 389-393. (Pubitemid 43845418)
12. Ushio-Fukai M, Tang Y, Fukai T, et al. (2002): Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res 91: 1160-1167. (Pubitemid 36076365)
13. Cai T, Fassina G, Morini M, et al. (1999): N-acetylcysteine inhibits endothelial cell invasion and angiogenesis. Lab Invest 79: 1151-1159. (Pubitemid 29444547)
14. Nijmeh J, Moldobaeva A, Wagner EM (2010): Role of ROS in ischemia-induced lung angiogenesis. Am J Physiol Lung Cell Mol Physiol 299: L535-L541.
15. Rak J, Mitsuhashi Y, Sheehan C, et al. (2000): Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res 60: 490-498. (Pubitemid 30070780)
16. Aluigi MG, De Flora S, D'Agostini F, et al. (2000): Antiapoptotic and antigenotoxic effects of N-acetylcysteine in human cells of endothelial origin. Anticancer Res 20: 3183-3187.
17. Prescott LF, Donovan JW, Jarvie DR, Proudfoot AT (1980): The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. Eur J Clin Pharmacol 37: 501-506.
18. Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA (2007): N-Acetylcysteine - a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol 7: 355-359. (Pubitemid 47289259)
19. Reliene R, Schiestl RH (2006): Antioxidant N-acetyl cysteine reduces incidence and multiplicity of lymphoma in Atm deficient mice. DNA Repair (Amst) 5: 852-859. (Pubitemid 43928890)
20. De Flora S, D'Agostini F, Masiello L, et al. (1996): Synergism between N-acetylcysteine and doxorubicin in the prevention of tumorigenicity and metastasis in murine models. Int J Cancer 67: 842-848. (Pubitemid 26348814)
21. D'Agostini F, Bagnasco M, Giunciuglio D, et al. (1998): Inhibition by oral N-acetylcysteine of doxorubicin-induced clastogenicity and alopecia, and prevention of primary tumors and lung micrometastases in mice. Int J Oncol 13: 217-224. (Pubitemid 28329207)
22. Cotter MA, Thomas J, Cassidy P, et al. (2007): N-acetylcysteine protects melanocytes against oxidative stress/damage and delays onset of ultraviolet-induced melanoma in mice. Clin Cancer Res 13: 5952-5958. (Pubitemid 47583923)
23. Redondo P, Bandrés E, Solano T, et al. (2000): Vascular endothelial growth factor (VEGF) and melanoma. N-acetylcysteine downregulates VEGF production in vitro. Cytokine 12: 374-378. (Pubitemid 30449829)
24. Cavalieri EL, Rogan EG (2011): Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer. J Steroid Biochem Mol Biol 125: 169-180.
25. Estensen RD, Levy M, Klopp SJ, et al. (1999): N-acetylcysteine suppression of the proliferative index in the colon of patients with previous adenomatous colonic polyps. Cancer Lett 147: 109-114.
26. Agarwal A, Mu?oz-Nájar U, Klueh U, et al. (2004): N-acetylcysteine promotes angiostatin production and vascular collapse in an orthotopic model of breast cancer. Am J Pathol 164: 1683-1696.
27. Lambert JD, Sang S, Yang CS (2008): N-Acetylcysteine enhances the lung cancer inhibitory effect of epigallocatechin-3-gallate and forms a new adduct. Free Radic Biol Med 44: 1069-1074.
28. van Zandwijk N, Dalesio O, Pastorino U, et al. (2000): EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 92: 977-986.
29. Liu C, Liu H, Li Y, et al. (2011): Intracellular glutathione content influences the sensitivity of lung cancer cell lines to methylseleninic acid. Mol Carcinog, doi: 10.1002/mc.20781.
30. Han YH, Park WH (2009): The effects of N-acetyl cysteine, buthionine sulfoximine, diethyldithiocarbamate or 3-amino- 1,2,4-triazole on antimycin A-treated Calu-6 lung cells in relation to cell growth, reactive oxygen species and glutathione. Oncol Rep 22: 385-391.
31. Kim KC, Lee C (2010): Curcumin induces downregulation of E2F4 expression and apoptotic cell death in HCT116 human colon cancer cells; involvement of reactive oxygen species. Korean J Physiol Pharmacol 14: 391-397.
32. Li B, Zhao J, Wang CZ, et al. (2011): Ginsenoside Rh2 induces apoptosis and paraptosis-like cell death in colorectal cancer cells through activation of p53. Cancer Lett 301: 185-192.
33. Lee SJ, Noh HJ, Sung EG, et al. (2011): Berberine sensitizes TRAIL-induced apoptosis through proteasome-mediated downregulation of c-FLIP and Mcl-1 proteins. Int J Oncol 38: 485-492.
34. Li J, Zuo L, Shen T, et al. (2003): Induction of apoptosis by sodium selenite in human acute promyelocytic leukemia NB4 cells: involvement of oxidative stress and mitochondria. J Trace Elem Med Biol 17: 19-26. (Pubitemid 36538168)
35. Bejarano I, Espino J, Barriga C, et al. (2011): Pro-oxidant effect of melatonin in tumour leucocytes: relation with its cytotoxic and pro-apoptotic effects. Basic Clin Pharmacol Toxicol 108: 14-20.
36. Park IJ, Lee YK, Hwang JT (2009): Green tea catechin controls apoptosis in colon cancer cells by attenuation of H2O2-stimulated COX-2 expression via the AMPK signaling pathway at low-dose H2O2. Ann N Y Acad Sci 1171: 538-544.
37. Block KI, Koch AC, Mead MN, et al. (2008): Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer 123: 1227-1239.
38. Lin PC, Lee MY, Wang WS, et al. (2006): N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data. Support Care Cancer 14: 484-487.
39. Myers C, Bonow R, Palmeri S, et al. (1983): A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol 10: 53-55. (Pubitemid 13092606)
40. Reliene R, Pollard JM, Sobol Z, et al. (2009): N-acetyl cysteine protects against ionizing radiation-induced DNA damage but not against cell killing in yeast and mammals. Mutat Res 665: 37-43.
41. Al-Tonbary Y, Al-Haggar M, El-Ashry R, et al. (2009): Vitamin E and N- acetylcysteine as antioxidant adjuvant therapy. Adv Haematol 4:1-5.
42. Albini A, Pennesi G, Donatelli F, et al. (2010): Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 102: 14-25.
43. van Dalen EC, Caron HN, Dickinson HO, Kremer LC (2008): Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev (6): CD003917.
44. Pela R, Calcagni AM, Subiaco S, et al. (1999): N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration 66: 495-500.
45. van Overveld FJ, Demkow U, Górecka D, et al. (2005): New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine. J Physiol Pharmacol 56 (Suppl 4): 135-142. (Pubitemid 43142774)
46. Decramer M, Rutten-van Mölken M, Dekhuijzen PN, et al. (2005): Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 365: 1552-1560. (Pubitemid 40615404)
47. Black PN, Morgan-Day A, McMillan TE, et al. (2004): Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease. BMC Pulm Med 4: 13-20.
48. Schermer T, Chavannes N, Dekhuijzen R, et al. (2009): Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir Med 103: 542-551.
49. Zuin R, Palamidese A, Negrin R, et al. (2005): High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clin Drug Investig 25: 401-408. (Pubitemid 41019987)
50. De Benedetto F, Aceto A, Dragani B, et al. (2005): Long-term oral N-acetylcysteine reduces exhaled hydrogen peroxide in stable COPD. Pulm Pharmacol Ther 18: 41-47. (Pubitemid 39647752)
51. Stav D, Raz M (2009): Effect of N-acetylcysteine on air trapping in COPD. A randomized placebo-controlled study. Chest 136; 381-386.
52. Grandjean EM, Berthet P, Ruffmann R, Leuenberger P (2000): Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 22: 209-221. (Pubitemid 30152100)
53. Stey C, Steurer J, Bachmann S, et al. (2000): The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J 16: 253-262. (Pubitemid 30624944)
54. Tirouvanziam R, Conrad CK, Bottiglieri T, et al. (2006): High-dose oral N-acetylcysteine, a glutation prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci U S A 103: 4628-4633.
55. Dauletbaev N, Fischer P, Aulbach B, et al. (2009): A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis. Eur J Med Res 14: 352-358.
56. Demedts M, Behr J, Buhl R, et al. (2005): High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 353: 2229-2242. (Pubitemid 41697286)
57. Behr J, Demedts M, Buhl R, et al. (2009): Lung function in idiopathic pulmonary fibrosis-extended analyses of the IFEGENIA trial. Respir Res 10: 101.
58. Bennett L, Crouse R, Feldstein D (2006): Clinical use of evidence- based medicine - clinical questions: acetylcysteine, a new treatment for an old foe? WMJ 105: 6-7.
59. Rahman I, MacNee W (2000): Regulation of redox glutathione and gene transcription in lung inflammation: therapeutic approaches. Free Radic Biol Med 28: 1405-1420. (Pubitemid 30621483)
60. Tomioka H, Kuwata Y, Imanaka K, et al. (2005). A pilot study of aerosolized N-acetylcysteine for idiopathic pulmonary fibrosis. Respirology 10: 449-455. (Pubitemid 43942613)
61. De Flora S, Grassi C, Carati L (1997): Attenuation of influenza- like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J 10: 1535-1541. (Pubitemid 27311068)
62. Aitio ML (2006): N-acetylcysteine - passe-partout or much ado about nothing? Br J Clin Pharmacol 61: 5-15.
63. Herzenberg LA, De Rosa SC, Dubs JG, et al. (1997): Glutathione deficiency is associated with impaired survival in HIV disease. Proc Natl Acad Sci USA 94: 1967-1972. (Pubitemid 27113945)
64. Ngô C, Chéreau C, Nicco C, et al. (2009): Reactive oxygen species controls endometriosis progression. Am J Pathol 175: 225-234.
65. Taylor RN, Yu J, Torres PB, et al. (2009): Mechanistic and therapeutic implications of angiogenesis in endometriosis. Reprod Sci 16: 140-146.
66. Larosa M, Facchini F, Pozzoli G, et al. (2010): Endometriosis: aehiopathogenic basis. Urologia 77 (Suppl 17): 1-11.
67. Foyouzi N, Berkkanoglu M, Arici A, et al. (2004): Effects of oxidants and antioxidants on proliferation of endometrial stromal cells. Fertil Steril 82 (Suppl 3): 1019-1022. (Pubitemid 39335910)
68. Wu Y, Guo SW (2006): Inhibition of proliferation of endometrial stromal cells by trichostatin A, RU486, CDB-2914, N-acetylcysteine, and ICI 182780. Gynecol Obstet Invest 62: 193-205. (Pubitemid 44763186)
69. Arumugam K, Dip YC (1995): Endometriosis and infertility: the role of exogenous lipid peroxides in the peritoneal fluid. Fertil Steril 63: 198-199.
70. Barcz E, Rózewska ES, Kaminski P, et al. (2002): Angiogenic activity and IL-8 concentrations in peritoneal fluid and sera in endometriosis. Int J Gynaecol Obstet 79: 229-235. (Pubitemid 35365776)
71. Donnez J, Smoes P, Gillerot S, et al. (1998): Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod 13: 1686-1690. (Pubitemid 28310515)
72. Scarpellini F, Sbracia M, Lecchini S, et al (2002): Antiangiogenesis treatment with thalidomide in endometriosis: a pilot study. Fertil Steril 78: 87.
73. Fulghesu AM, Ciampelli M, Muzj G, et al. (2002): N-acetylcysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome. Fertil Steril 77: 1128-1135. (Pubitemid 34626318)
74. Masha A, Manieri C, Dinatale S, et al. (2009): Prolonged treatment with N-acetylcysteine and L-arginine restores gonadal function in patients with polycystic ovary syndrome. J Endocrinol Invest 32: 870-872.
75. Rizk AY, Bedaiwy MA, Al-Inany HG (2005): N-acetylcysteine is a novel adjuvant to clomiphene citrate in clomiphene citrate-resistant patients with polycystic ovary syndrome. Fertil Steril 83: 367-370. (Pubitemid 40221790)
76. Badawy A, State O, Abdelgawad S (2007): N-acetyl cysteine and clomiphene citrate for induction of ovulation in polycystic ovary syndrome: a cross-over trial. Acta Obstet Gynecol Scand 86: 218-222.
77. Nasr A (2010): Effect of N-acetyl-cysteine after ovarian drilling in clomiphene citrate-resistant PCOS women: a pilot study. Reprod Biomed Online 20: 403-409.
78. Abu Hashim H, Anwar K, El-Fatah RA (2010): N-acetyl cysteine plus clomiphene citrate versus metformin and clomiphene citrate in treatment of clomiphene-resistant polycystic ovary syndrome: a randomized controlled trial. J Womens Health (Larchmt) 19: 2043-2048.
79. Briguori C, Colombo A, Airoldi F, et al. (2004): N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agentassociated nephrotoxicity. J Am Coll Cardiol 44: 762-765. (Pubitemid 39099569)
80. Bagshaw SM, McAlister FA, Manns BJ, Ghali WA (2006): Acetylcysteine in prevention of contrast-induced nephropathy: a case study of pitfalls in the evolution of evidence. Arch Intern Med 166: 161-166. (Pubitemid 43144938)
81. Kelly AM, Dwamena B, Cronin P, et al. (2008): Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 148: 284-294. (Pubitemid 351665489)
82. Augustin AJ (2010): Oxidative tissue damage. Klin Monbl Augenheilkd 227: 90-98 [Article in German].
83. Pazdro R, Burgess JR (2010): The role of vitamin E and oxidative stressing diabetes complications. Mech Aging Dev 131: 276-286.
84. Kern TS, Engerman RL (1995): Galactose-induced retinal microangiopathy in rats. Invest Ophthalmol Vis Sci 36: 490-496.
85. Ho E, Chen G, Bray TM (1999): Supplementation of N-acetylcysteine inhibits NFκB activation and protects against alloxan- induced diabetes in CD-1 mice. Faseb J 13: 1845-1854. (Pubitemid 29473348)
86. Gibson KR, Winterburn TJ, Barrett F, et al. (2011): Therapeutic potential of N-acetylcysteine as an antiplatelet agent in patients with type-2 diabetes. Cardiovasc Diabetol 10: 43.
87. Tsai GY, Cui JZ, Syed H, et al. (2009): Effect of N-acetylcysteine on the early expression of inflammatory markers in the retina and plasma of diabetic rats. Clin Experiment Ophthalmol 37: 223-231.
88. Xu KP, Li Y, Ljubimov AV, Yu FS (2009): High glucose suppresses epidermal growth factor receptor/phosphatidylinositol 3-kinase/Akt signaling pathway and attenuates corneal epithelial wound healing. Diabetes 58: 1077-1085.
89. Yang D, Elner SG, Chen X, et al. (2011): MCP-1-activated monocytes induce apoptosis in human retinal pigment epithelium. Invest Ophthalmol Vis Sci 52: 6026-6034.
90. Kalariya NM, Ramana KV, Srivastava SK, van Kuijk FJ (2009): Genotoxic effects of carotenoid breakdown products in human retinal pigment epithelial cells. Curr Eye Res 34: 737-747.
91. Kalariya NM, Ramana KV, Srivastava SK, van Kuijk FJ (2008): Carotenoid derived aldehydes-induced oxidative stress causes apoptotic cell death in human retinal pigment epithelial cells. Exp Eye Res 86: 70-80. (Pubitemid 350212880)
92. Hara R, Inomata Y, Kawaji T, et al. (2010): Suppression of choroidal neovascularization by N-acetyl-cysteine in mice. Curr Eye Res 35: 1012-1020.
93. Walters MT, Rubin CE, Keightley SJ, et al. (1986): A double-blind, cross-over, study of oral N-acetylcysteine in Sjögren's syndrome. Scand J Rheumatol Suppl 61: 253-258. (Pubitemid 17120372)
94. Akyol-Salman I, Azizi S, Mumcu U, Baykal O (2010): Efficacy of topical N-acetylcysteine in the treatment of meibomian gland dysfunction. J Ocul Pharmacol Ther 26: 329-333.
95. Kahn HA, Leibowitz HM, Ganley JP, et al. (1977): The Framingham Eye Study. I. Outline and major prevalence findings. Am J Epidemiol 106: 17-32. (Pubitemid 8160455)
96. Sardi B (1995): Eradicating cataracts. Townsend Letter for Doctors; 50-60.
97. Jain AK, Lim G, Langford M, Jain SK (2002): Effect of high-glucose levels on protein oxidation in cultured lens cells, and in crystalline and albumin solution and its inhibition by vitamin B6 and N-acetylcysteine: its possible relevance to cataract formation in diabetes. Free Radic Biol Med 33: 1615-1621. (Pubitemid 35462002)
98. Lieberman MW, Wiseman AL, Shi ZZ, et al. (1996): Growth retardation and cysteine deficiency in γ-glutamyl transpeptidase- deficient mice. Proc Natl Acad Sci U S A 93: 7923-7926. (Pubitemid 26277140)
99. Zhang S, Chai FY, Yan H, et al. (2008): Effects of N-acetylcysteine and glutathione ethyl ester drops on streptozotocin-induced diabetic cataract in rats. Mol Vis 14: 862-870. (Pubitemid 351715814)